In the rapidly evolving landscape of oncology, the advent of liquid biopsy technologies has ushered in a transformative era for cancer diagnosis and treatment stratification. One of the most compelling…
Source: Dr. P. Marazzi/Science Photo Library / Getty Images It is well established that glioblastomas are one of the deadliest brain cancers with a median survival rate of about 15…
Credit: Nemes Laszlo/Science Photo Library/Getty Images Researchers at the Keck School of Medicine of University of Southern California (USC) have developed a new type of chimeric antigen receptor (CAR) T…
Findings from a new study led by scientists at Stanford University School of Medicine and their colleagues elsewhere show that a single signaling pathway controls whether immune cells attack or…
A 3D virtual model of the PKMYT1–PROTAC–CRBN ternary complex depicting how Insilico Medicine’s bifunctional proteolysis-targeting chimera (PROTAC) D16-M1P2 (shown in yellow) inhibits membrane-associated tyrosine-threonine protein kinase 1 (PKMYT1, shown in…
View eBook With the MiSeq™ i100 Series, Illumina continues to set the highest standards. Advancements in system design, sequencing chemistry, and data analysis deliver the simplest, fastest benchtop sequencing and…
Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant forms of breast cancer. It grows quickly, spreads early and lacks the hormone receptors that make other breast…
Freenome is taking itself public via a special purpose acquisition company, also known as a SPAC deal, to help raise funds in preparation for the planned 2026 launch of its…
Researchers at the University of Colorado (UC) Denver, Anschutz Medical Campus, have discovered a novel combination treatment strategy that could offer new hope to ovarian cancer patients who stop responding…
When infection or injury occurs, neutrophils—our most abundant immune cells—are the first to arrive. Long considered short-lived foot soldiers of the immune system, they are essential for host defense yet…